TG Therapeutics (TGTX) to Release Quarterly Earnings on Monday

TG Therapeutics (NASDAQ:TGTX) will likely be announcing its Q1 2026 results before the market opens on Monday, May 4th. Analysts expect the company to announce earnings of $0.25 per share and revenue of $198.1620 million for the quarter. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Monday, May 4, 2026 at 8:30 AM ET.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.35 by ($0.21). TG Therapeutics had a return on equity of 101.12% and a net margin of 72.56%.The company had revenue of $192.57 million for the quarter, compared to analyst estimates of $192.15 million. During the same period last year, the company posted $0.15 EPS. The business’s revenue for the quarter was up 78.0% on a year-over-year basis. On average, analysts expect TG Therapeutics to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

TG Therapeutics Stock Performance

Shares of TGTX stock opened at $36.62 on Monday. TG Therapeutics has a one year low of $25.28 and a one year high of $46.48. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.29 and a current ratio of 4.10. The company has a 50 day moving average price of $31.69 and a 200 day moving average price of $31.48. The firm has a market capitalization of $5.85 billion, a price-to-earnings ratio of 13.22 and a beta of 1.76.

Wall Street Analysts Forecast Growth

TGTX has been the subject of several research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of TG Therapeutics in a research report on Wednesday, January 14th. The Goldman Sachs Group upped their price target on TG Therapeutics from $37.00 to $39.00 and gave the stock a “neutral” rating in a research note on Thursday, January 15th. Wall Street Zen lowered TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. JPMorgan Chase & Co. dropped their price target on TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating for the company in a research note on Monday, February 2nd. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of TG Therapeutics in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $50.00.

Institutional Investors Weigh In On TG Therapeutics

Several large investors have recently made changes to their positions in the business. Invesco Ltd. increased its position in shares of TG Therapeutics by 47.1% in the fourth quarter. Invesco Ltd. now owns 1,609,815 shares of the biopharmaceutical company’s stock worth $47,989,000 after acquiring an additional 515,481 shares in the last quarter. Corient Private Wealth LLC increased its position in shares of TG Therapeutics by 3.6% in the fourth quarter. Corient Private Wealth LLC now owns 41,764 shares of the biopharmaceutical company’s stock worth $1,245,000 after acquiring an additional 1,469 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new stake in shares of TG Therapeutics in the fourth quarter valued at about $212,000. Empowered Funds LLC acquired a new stake in shares of TG Therapeutics in the fourth quarter valued at about $1,698,000. Finally, nVerses Capital LLC purchased a new stake in shares of TG Therapeutics during the 4th quarter valued at about $250,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.